Jordyn Sava

Jordyn Sava is an editor for Targeted Oncology.

Articles

FDA Grants Orphan Drug Designation to VCN-01 for Retinoblastoma Treatment

February 9th 2022

The novel oncolytic adenovirus, VCN-01 has been granted FDA orphan drug designation for retinoblastoma and will soon be investigated in a phase 2/3 clinical trial.

Lack of New Therapies For AML Remains a Challenge For Oncologists

Jordyn Sava

February 8th 2022

Acute myeloid leukemia has one of the highest unmet needs for new therapies out of all human cancers, according to Marcin Kortylewski.

FDA Investigates Possible Increased Risk of Death Associated With Umbralisib in Lymphoma

Jordyn Sava

February 7th 2022

Umbralisib is potentially linked to an increased risk of death in patients with lymphomas, according to an alert for clinical and patients announced by the FDA.

Frontline Brentuximab Vedotin Added to Chemotherapy Prolongs Survival in Advanced cHL

Jordyn Sava

February 4th 2022

Based on data from phase 3 ECHELON-1 brentuximab vedotin in combination with chemotherapy extends survival in patients with advanced classical Hodgkin lymphoma.

Research Explores Possible Link Between Gut Microbiome and Better Outcomes in Kidney Cancer

Jordyn Sava

February 3rd 2022

In an interview with Targeted Oncology, Nazli Dizman, MD, discussed the role of gut microbiome in cancer and speaks to her presentation given at IKCS.